APR 16, 2015 09:27 AM PDT

Tumor-Only Genetic Sequencing May Mislead Cancer Therapy

When it comes to sequencing patients' tumor genomes to personalize cancer therapy, one very important step may be missing, suggest Johns Hopkins researchers: a point of comparison to patients' noncancerous genomes.
Johns Hopkins researchers cite the importance of comparing patients' cancerous and noncancerous genomes.
Without these comparisons - or a full picture of a patient's genome - nearly half of all patients may be getting the wrong cancer treatment, say the researchers at the John Hopkins Kimmel Cancer Center.

"By not sequencing each person's normal tissue to filter out noncancer-related changes, it's difficult to really understand what is occurring in the tumor," said Victor Velculescu, M.D., Ph.D., a professor of oncology and pathology and co-director of the Cancer Biology Program at the Johns Hopkins University School of Medicine, in a press release.

The study appears today in Science Translational Medicine.

When Velculescu and colleagues compared the genomes of tumor and normal tissue from more than 800 cancer patients' sequencing data, they found that approximately 65 percent of the genetic changes identified with tumor-only genetic sequencing were "false positives" and not related to the patient's cancer. That's because, by first sequencing a patient's noncancer genome, the researchers identified which genetic changes are heritable variations.

The researchers also looked at changes in "actionable genes," or genes for which some drug or therapy has been identified. In this case, false positive affected 48 percent of the patients analyzed.

"In tumor-only analyses, we found that nearly half of patients had tumor mutations that were actually germline or false positives in actionable genes, and they could lead to inappropriate therapy," Velculescu said.

Inaccurate genetic information can lead to side effects from incorrect targeted therapies and increased costs of patient care from misdirected medicines, report the researchers.

That said, Velculescu and his team acknowledge the challenges associated with implementing tumor-normal analyses in a clinical setting - including added costs of sequencing a patient's normal tissue.

These study results build on the concept of precision medicine, in which oncology researchers hope that one day, DNA sequencing will be a reality for every cancer patient, so that patients may receive personalized therapy.

By Stephanie Guzowski, Editor, Drug Discovery News
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUL 03, 2018
Cancer
JUL 03, 2018
Hereditary Myeloid Neoplasm Predisposition
New changes in myeloid classification help to outline a new category of AML which develops as a result of hereditary mutations predisposing family members to myeloid neoplasms in adulthood....
JUL 10, 2018
Cancer
JUL 10, 2018
Risk Allele Variant SNP at 14q11.2 Linked to ALL
Researchers utilized genome-wide association studies to identify a variant SNP within a gene at 14q11.2 which is linked to ALL....
JUL 17, 2018
Cancer
JUL 17, 2018
Large Multifactorial NIH Study Announced for Prostate Cancer Aggressiveness in African-American Men
The largest coordinated study on Prostate cancer aims to look at both genetic and environmental factors that lead to increased risk and cancer aggressiveness in African-American men compared...
AUG 02, 2018
Genetics & Genomics
AUG 02, 2018
The Genetic Hotspots That Can Lead to Cancer
In some of our body's tissues, cells have to replicate many times. That introduces a chance for new genetic errors every time....
AUG 21, 2018
Cancer
AUG 21, 2018
'Zombie' gene returns to life and kills cancer in elephants
Researchers have discovered a gene that can protect elephants from cancer. An estimated 17 percent of humans worldwide die from cancer, but less than five ...
SEP 15, 2018
Clinical & Molecular DX
SEP 15, 2018
Cancer & Anoikis: A Match Not Made in Heaven
Anoikis have always been intimately entwined with cancer, henceforth the quest to seek how they came to be as such....
Loading Comments...